IPSC

Century Therapeutics Inc

1.52

Nov 03 • 3:59 PM ET +0.04 (2.70%)

1.52

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: SANA FATE VRTX CABA KYTX ALLO NKTX CRBU CRSP SNY

| Held by: VTI IWM VXF IWN VTWO IWC OMFS VHT AVSC FESM

Scroll to Statements

Index	RUT
Market Cap	275.23M
Enterprise Value	194.19M
Income	-109.79M
Sales	0.00M
Book/sh	1.29
Cash/sh	0.66
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	78
IPO	Jun 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.18
P/C	2.30
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.28
Current Ratio	8.28
Debt/Eq	0.17
LT Debt/Eq	0.15
Option/Short	Yes / Yes

EPS (ttm)	-0.90
EPS next Y	-0.45
EPS next Q	-0.12
EPS this Y	-274.29%
EPS next Y	14.44%
EPS next 5Y	-
EPS past 3/5Y	63.45% 35.31%
Sales past 3/5Y	175.88% -
EPS Y/Y TTM	-219.52%
Sales Y/Y TTM	-100.00%
EPS Q/Q	55.50%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	-54.55% -

Insider Own	32.08%
Insider Trans	-0.02%
Inst Own	65.96%
Inst Trans	11.31%
ROA	-38.41%
ROE	-49.65%
ROIC	-41.12%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.61%
SMA50	-11.30%
SMA200	-27.22%
Trades

Shs Outstand	180.55M
Shs Float	122.98M
Short Float	23.69%
Short Ratio	42.68
Short Interest	29.13M
52W High	3.04 -50.00%
52W Low	0.44 249.43%
Volatility	7.33% 10.23%
ATR (14)	0.14
RSI (14)	48.18
Beta	1.77
Rel Volume	1.13
Avg Volume	682.67K
Volume	773,530

Perf Week	4.83%
Perf Month	2.70%
Perf Quarter	-22.45%
Perf Half Y	-33.62%
Perf YTD	52.79%
Perf Year	153.33%
Perf 3Y	-13.64%
Perf 5Y	-93.45%
Perf 10Y	-
Recom	1.33
Target Price	5.12
Prev Close	1.48
Price	1.52
Change %	2.70%

Consensus

Strong Buy

Avg. Price Target

$5.12

Implied Upside

+236.8%

Analysts11incl. previous ratings

Rating Distribution9 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 27, 2026	Initiated	MMizuho	Outperform	$8	+426.3%
Feb 25, 2026	Initiated	TTD Cowen	Buy
Aug 08, 2024	Initiated	RRodman & Renshaw	Buy	$6	+294.7%
Aug 28, 2023	Downgrade	JJP Morgan	Overweight → Neutral	$28 → $5	+228.9%
Dec 27, 2022	Initiated	CChardan Capital Markets	Buy	$19	+1,150.0%
Oct 31, 2022	Initiated	GGuggenheim	Buy	$15	+886.8%
Oct 10, 2022	Initiated	CCanaccord Genuity	Buy	$28	+1,742.1%
May 23, 2022	Initiated	HH.C. Wainwright	Buy	$27	+1,676.3%
May 12, 2022	Initiated	WWilliam Blair	Mkt Perform
Jul 13, 2021	Initiated	PPiper Sandler	Overweight	$38	+2,400.0%
Jul 13, 2021	Initiated	JJP Morgan	Overweight	$40	+2,531.6%
Jul 13, 2021	Initiated	BBofA Securities	Buy	$34	+2,136.8%

Oct-14-26 08:05AM	Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-02-26 08:05AM	Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 (GlobeNewswire)
Sep-09-26 04:05PM	Century Therapeutics Appoints Joseph Truitt to Board of Directors (GlobeNewswire)
Aug-12-26 08:00AM	Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Jul-09-26 08:00AM	Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D Clinical & Research Congress 2026 (GlobeNewswire)
04:05PM	Loading…
Jun-08-26 04:05PM	New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 (GlobeNewswire)
May-13-26 08:00AM	Century Therapeutics Reports First Quarter Financial Results and Business Updates (GlobeNewswire)
Apr-30-26 04:05PM	Century Therapeutics Selected for Oral Presentation of CNTY-813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire)
Mar-12-26 08:00AM	Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates (GlobeNewswire) -8.42%
Feb-25-26 08:00AM	Century Therapeutics to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Jan-30-26 02:58PM	Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission (Insider Monkey) -5.47%
Jan-22-26 12:00PM	Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +13.24%
Jan-08-26 08:00AM	Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes (GlobeNewswire) +36.15%
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks) +44.44%
08:55AM	Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain (Zacks)
08:55AM	Loading…
Dec-09-25 08:55AM	Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors (Zacks)
08:00AM	Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors (GlobeNewswire)
Nov-25-25 04:01PM	Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 07:30AM	Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -17.54%
07:00AM	Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes (GlobeNewswire)
Oct-14-25 04:01PM	Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-22-25 08:00AM	Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 04:01PM	Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-21-25 12:00PM	All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy (Zacks)
Jul-15-25 08:50AM	Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock (Zacks)
Jun-25-25 08:50AM	Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Jun-06-25 08:50AM	Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain (Zacks) +9.47%
May-28-25 04:01PM	Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress (GlobeNewswire)
May-15-25 08:15PM	Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates (Zacks) +5.79% +8.23%
04:01PM	Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
05:10PM	Loading…
May-14-25 05:10PM	Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.02%
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 10:01AM	Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:20AM	Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-28-25 04:30PM	Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-15-25 04:01PM	Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 (GlobeNewswire)
Mar-25-25 12:00PM	Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-19-25 05:15PM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.66%
04:01PM	Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jan-21-25 07:00AM	Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders (GlobeNewswire)
Nov-26-24 07:00AM	Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 12:00PM	What Makes Century Therapeutics (IPSC) a New Buy Stock (Zacks)
Nov-05-24 10:15AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
09:05AM	Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
09:00AM	Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-04-24 07:00AM	Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-26-24 07:00AM	Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer (GlobeNewswire)
Aug-08-24 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-09-24 12:00PM	Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-03-24 07:00AM	Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting (GlobeNewswire)
May-10-24 03:35PM	Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ... (GuruFocus.com)
07:00AM	Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting (GlobeNewswire)
May-09-24 01:54PM	IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:40AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-23-24 07:00AM	Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-11-24 08:25AM	Century buys a startup, raises funding in cell therapy expansion (BioPharma Dive) +7.14%
07:00AM	Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics (GlobeNewswire)
Apr-08-24 04:05PM	Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.08%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) -9.48%
Mar-19-24 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Mar-14-24 01:52PM	IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.20%
07:30AM	Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-08-24 11:55PM	Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares (GuruFocus.com)
Mar-07-24 09:55AM	How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4% (Zacks) +6.30%
Mar-05-24 06:03PM	Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.65%
Feb-01-24 07:00AM	Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-09-23 12:00PM	Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits (GlobeNewswire)
Dec-07-23 11:01AM	Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study (Zacks) +8.37%
Dec-06-23 07:30AM	Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus (GlobeNewswire) +36.08%
07:30AM	Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-21-23 07:00AM	Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 03:58PM	FMR LLC Adjusts Position in Century Therapeutics Inc (GuruFocus.com)
Nov-09-23 08:29AM	Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results (GuruFocus.com) -13.13%
07:01AM	Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer (GlobeNewswire)
07:00AM	Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-02-23 09:00AM	Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits at the 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-26-23 07:00AM	Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-09-23 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-23 06:48AM	Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago (Simply Wall St.)
May-12-23 06:11AM	Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-17-23 07:00AM	Century Therapeutics to Present at Chardans 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit (GlobeNewswire)
Apr-12-23 08:30AM	Century Therapeutics Announces Leadership Changes (GlobeNewswire) -7.91%
Mar-16-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-15-23 04:01PM	Century Therapeutics to Present at the AACR Annual Meeting 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-23 07:30AM	Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas (GlobeNewswire)
Feb-01-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:35AM	After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC) (Zacks) -7.36%
Jan-09-23 10:46AM	Century Therapeutics becomes latest life sciences company to enact layoffs, narrow focus (American City Business Journals)
Jan-06-23 08:23AM	Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive (Benzinga)
Jan-05-23 04:01PM	Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire)
Jan-04-23 07:00AM	Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carr Douglas	Officer	Nov 03 '26	Proposed Sale	1.52	266	404		Nov 03 03:32 PM
Russotti Gregory	See Remarks	Sep 14 '26	Sale	1.93	2,587	4,993	509,198	Sep 15 06:25 PM
Carr Douglas	SVP Finance & Operations	Sep 14 '26	Sale	1.93	1,658	3,200	502,907	Sep 15 06:25 PM
Russotti Gregory	Officer	Sep 14 '26	Proposed Sale	1.93	2,587	4,994		Sep 14 03:31 PM
Carr Douglas	Officer	Sep 14 '26	Proposed Sale	1.93	1,658	3,201		Sep 14 03:29 PM
Russotti Gregory	See Remarks	Sep 08 '26	Sale	2.05	534	1,095	511,785	Sep 09 04:35 PM
Carr Douglas	SVP Finance & Operations	Sep 08 '26	Sale	2.05	254	521	504,565	Sep 09 04:34 PM
Russotti Gregory	Officer	Sep 08 '26	Proposed Sale	2.05	534	1,094		Sep 08 03:10 PM
Carr Douglas	SVP Finance & Operations	Aug 03 '26	Sale	1.98	275	544	504,819	Aug 05 04:08 PM
Russotti Gregory	See Remarks	Jun 12 '26	Sale	2.23	2,584	5,767	512,319	Jun 15 07:57 PM
Carr Douglas	SVP Finance & Operations	Jun 12 '26	Sale	2.23	1,654	3,692	505,094	Jun 15 07:56 PM
Russotti Gregory	Officer	Jun 12 '26	Proposed Sale	2.23	2,584	5,768		Jun 12 03:35 PM
Russotti Gregory	See Remarks	Jun 08 '26	Sale	2.11	524	1,106	514,903	Jun 09 04:10 PM
Carr Douglas	SVP Finance & Operations	Jun 08 '26	Sale	2.11	249	526	506,748	Jun 09 04:10 PM
Russotti Gregory	Officer	Jun 08 '26	Proposed Sale	2.11	524	1,106		Jun 08 03:28 PM
Carr Douglas	SVP Finance & Operations	May 04 '26	Sale	2.34	264	618	506,997	May 06 05:27 PM
Carr Douglas	SVP Finance & Operations	Mar 12 '26	Sale	2.55	7,043	17,953	507,261	Mar 16 04:04 PM
Russotti Gregory	See Remarks	Mar 12 '26	Sale	2.55	10,076	25,684	515,427	Mar 16 04:03 PM
Russotti Gregory	Officer	Mar 12 '26	Proposed Sale	2.55	10,076	25,686		Mar 12 04:23 PM
Russotti Gregory	See Remarks	Mar 09 '26	Sale	2.54	479	1,215	525,503	Mar 11 04:11 PM
Russotti Gregory	Officer	Mar 09 '26	Proposed Sale	2.54	479	1,215		Mar 09 03:15 PM
Carr Douglas	SVP Finance & Operations	Feb 03 '26	Sale	1.82	323	589	514,551	Feb 05 04:14 PM
Cowan Chad	Chief Scientific Officer	Dec 22 '25	Buy	0.85	58,060	49,252	1,045,087	Dec 29 04:52 PM
Pfeiffenberger Brent	President and CEO	Dec 12 '25	Buy	0.58	52,000	30,352	3,322,990	Dec 16 06:38 PM
Carr Douglas	SVP Finance & Operations	Dec 08 '25	Sale	0.53	257	137	404,874	Dec 10 04:34 PM
Russotti Gregory	See Remarks	Dec 08 '25	Sale	0.53	526	280	390,982	Dec 10 04:34 PM
Pfeiffenberger Brent	Officer	Dec 08 '25	Proposed Sale	0.53	476	253		Dec 08 03:29 PM
Russotti Gregory	Officer	Dec 08 '25	Proposed Sale	0.53	526	280		Dec 08 03:17 PM
Cowan Chad	Chief Scientific Officer	Nov 20 '25	Sale	0.50	5,462	2,736	987,027	Nov 24 04:05 PM
Pfeiffenberger Brent	President and CEO	Nov 19 '25	Buy	0.50	35,000	17,328	3,271,453	Nov 20 06:02 PM
Cowan Chad	Officer	Nov 20 '25	Proposed Sale	0.50	5,462	2,739		Nov 20 03:15 PM
Pfeiffenberger Brent	President and CEO	Nov 17 '25	Sale	0.45	32,456	14,735	3,236,453	Nov 19 04:19 PM
Pfeiffenberger Brent	Officer	Nov 17 '25	Proposed Sale	0.45	32,456	14,732		Nov 17 04:16 PM

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Pharm.D.Dr. Brent Pfeiffenberger M.B.A.

Chief Technology & Manufacturing OfficerDr. Gregory Russotti Ph.D.

Chief Scientific OfficerDr. Chad A. Cowan Ph.D.

Senior VP of Finance & OperationsMr. Douglas Carr CPA

Ph.D.Krista Kauppinen J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IPSC

Century Therapeutics Inc

Upgrade your Finviz experience